title: Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa).
abstract: Seeking insight into the possible role of estrogens in prostate cancer (PCa) evolution, we assayed serum E2, estrone (E1), and estrone sulfate (E1S) in 349 PCa and 100 benign prostatic hyperplasia (BPH) patients, and in 208 control subjects in the same age range (50-74 years). E1 (pmol/L+/-S.D.) and E1S (nmol/L+/-S.D.) in the PCa and BPH patients (respectively 126.1+/-66.1 and 2.82+/-1.78, and 127.8+/-56.4 and 2.78+/-2.12) were significantly higher than in the controls (113.8+/-47.6 and 2.11+/-0.96). E2 was not significantly different among the PCa, BPH, and control groups. These assays were also carried out in PCa patients after partition by prognosis (PSA, Gleason score (GS), histological stage, and surgical margins (SM)). Significantly higher E1S levels were found in PCa with: PSA>10 ng/L (3.05+/-1.92) versus PSA<or=10 ng/mL (2.60+/-1.55), stage pT3-T4 (2.99+/-1.80) versus pT2 (2.58+/-1.58), and positive (3.26+/-1.95) versus negative margins (2.52+/-1.48). E1 was higher in poor- than in better-prognosis PCa. E2 was significantly higher in PCa with GS>or=4+3 (109.5+/-43.8) versus GS<or=3+4 (100.6+/-36.5) and increased significantly when GS increased from 3+3 to 4+4. Estrogens, especially E1S appeared to be possible markers of PCa progression. Attempting to identify potential sources of E2 in PCa according to prognosis, as well as in BPH, we found a significant correlation coefficient between E1S and E2 (0.266-0.347) in poor-prognosis PCa and no correlation in BPH (0.026) and better-prognosis PCa (0.013-0.104). It is as though during progression of PCa from good to poor prognosis there were a shift in the E1 to E2 metabolic pathway from predominantly oxidative to predominantly reductive.
authors.affiliation: AP-HP CIB INSERM IMRB U841eq07, Henri Mondor, Faculté de Médecine, 94010 Créteil, France. giton@univ-paris12.fr
authors.forename: Frank
authors.initials: F
authors.lastname: Giton
authors.forename: Alexandre
authors.initials: A
authors.lastname: de la Taille
authors.forename: Yves
authors.initials: Y
authors.lastname: Allory
authors.forename: Hervé
authors.initials: H
authors.lastname: Galons
authors.forename: Francis
authors.initials: F
authors.lastname: Vacherot
authors.forename: Pascale
authors.initials: P
authors.lastname: Soyeux
authors.forename: Claude Clément
authors.initials: CC
authors.lastname: Abbou
authors.forename: Sylvain
authors.initials: S
authors.lastname: Loric
authors.forename: Olivier
authors.initials: O
authors.lastname: Cussenot
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Raynaud
authors.forename: Jean
authors.initials: J
authors.lastname: Fiet
mesh_terms: D000328:Adult; D000368:Aged; D000728:Androgens / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D001774:Blood Chemical Analysis / Q000706:statistics & numerical data; D016022:Case-Control Studies; D004958:Estradiol / Q000097:blood; D004970:Estrone / Q000031:analogs & derivatives* / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology; D012016:Reference Values
chemical_list: D000728:Androgens; D014408:Biomarkers, Tumor; D004970:Estrone; D004958:Estradiol; C017296:estrone sulfate